ALKS 5461 clinical trials
Also written ALKS 5461.
How each study uses ALKS 5461 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALKS 5461
- 17
Studies by the year they started
17 studies that test it; most in 2014 (7)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2014 | 7 |
| 2015 | 6 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Studies
Open first, then newest update. How each study uses ALKS 5461 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)TerminatedPhase 3Alkermes, Inc.NCT03610048Written as ALKS 5461
- A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)CompletedPhase 3Alkermes, Inc.NCT03188185Written as ALKS 5461
- A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)CompletedPhase 3Alkermes, Inc.NCT02085135Written as ALKS 5461
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 StudyCompletedPhase 3Alkermes, Inc.NCT02218008Written as ALKS 5461
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 StudyCompletedPhase 3Alkermes, Inc.NCT02158533Written as High Dose ALKS 5461
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 StudyCompletedPhase 3Alkermes, Inc.NCT02158546Written as ALKS 5461
- A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)CompletedPhase 2Alkermes, Inc.NCT01500200Written as ALKS 5461
- A Long-Term Safety Study of ALKS 5461CompletedPhase 3Alkermes, Inc.NCT02141399Written as ALKS 5461
- Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedPhase 1Alkermes, Inc.NCT02452801Written as ALKS 5461
- Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal FunctionCompletedPhase 1Alkermes, Inc.NCT02508506Written as ALKS 5461
- A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02479308Written as ALKS 5461
- A Water Consumption Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02521857Written as ALKS 5461
- A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid UsersCompletedPhase 1Alkermes, Inc.NCT02413281Written as ALKS 5461
- A Drug-drug Interaction Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02545439Written as ALKS 5461
- A Drug-Drug Interaction Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02272764Written as ALKS 5461
- A Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02068105Written as ALKS 5461
- ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDDCompletedPhase 1/2Alkermes, Inc.NCT01381107Written as ALKS 5461